116 related articles for article (PubMed ID: 36201657)
41. Comparison of Covid-19 antibody status after vaccination between residents in long-term geriatric care and residents assisted-living facilities.
Naschitz JE; Kertes J; Pinto G; Zaigraykin N; Oz D; Goland E; Nasser S; Supino-Rosin L; Lazar R; Ekka-Zohar A
Infect Dis (Lond); 2022 Apr; 54(4):292-296. PubMed ID: 34918582
[TBL] [Abstract][Full Text] [Related]
42. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination.
Eren-Kutsoylu OO; Appak O; Nazli-Zeka A; Omeroglu-Simsek G; Tekin N; Bayram B; Sayiner AA; Tanglay N; Avkan-Oguz V
Ir J Med Sci; 2023 Feb; 192(1):263-268. PubMed ID: 35829907
[TBL] [Abstract][Full Text] [Related]
44. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
[TBL] [Abstract][Full Text] [Related]
45. Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19.
Adhikari B; Bednash JS; Horowitz JC; Rubinstein MP; Vlasova AN
Front Immunol; 2024; 15():1325243. PubMed ID: 38390335
[TBL] [Abstract][Full Text] [Related]
46. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
47. The Effect of Gestational Age at BNT162b2 mRNA Vaccination on Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Levels.
Rottenstreich A; Zarbiv G; Oiknine-Djian E; Vorontsov O; Zigron R; Kleinstern G; Wolf DG; Porat S
Clin Infect Dis; 2022 Aug; 75(1):e603-e610. PubMed ID: 35171998
[TBL] [Abstract][Full Text] [Related]
48. Association between a low response to rubella vaccination and reduced anti-severe acute respiratory syndrome coronavirus 2 immune response after vaccination with BNT162b2: a cross-sectional study.
Nakaharai K; Nakazawa Y; Mishima Y; Saito M; Shinozaki Y; Yoshida M
Clin Microbiol Infect; 2023 Feb; 29(2):253.e1-253.e5. PubMed ID: 36150670
[TBL] [Abstract][Full Text] [Related]
49. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
50. BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort.
Goldin S; Adler L; Azuri J; Mendel L; Haviv S; Maimon N
Gerontology; 2022; 68(12):1350-1357. PubMed ID: 35134810
[TBL] [Abstract][Full Text] [Related]
51. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
[TBL] [Abstract][Full Text] [Related]
52. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
[TBL] [Abstract][Full Text] [Related]
53. Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy.
Kugelman N; Nahshon C; Shaked-Mishan P; Cohen N; Sher ML; Gruber M; Marom I; Zolotarevsky A; Lavie O; Damti A; Zilberlicht A; Bardicef M; Kedar R
JAMA Pediatr; 2022 Mar; 176(3):290-295. PubMed ID: 34932066
[TBL] [Abstract][Full Text] [Related]
54. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
55. Comment on: "Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities: the GeroCovid Study".
Kow CS; Ramachandram DS; Hasan SS; Thiruchelvam K
Drugs Aging; 2024 Mar; 41(3):283-285. PubMed ID: 38416396
[No Abstract] [Full Text] [Related]
56. Humoral immunity induced by mRNA COVID-19 vaccines in Nursing Home Residents previously infected with SARS-CoV-2.
Fedele G; Palmieri A; Damiano C; Di Lonardo A; Leone P; Schiavoni I; Trevisan C; Abbatecola AM; Cafariello C; Malara A; Minchella P; Panduri G; Antonelli Incalzi R; Palamara AT; Stefanelli P; Onder G;
Aging Clin Exp Res; 2022 Oct; 34(10):2577-2584. PubMed ID: 36127623
[TBL] [Abstract][Full Text] [Related]
57. Comparison of Maternal and Neonatal Antibody Levels After COVID-19 Vaccination vs SARS-CoV-2 Infection.
Flannery DD; Gouma S; Dhudasia MB; Mukhopadhyay S; Pfeifer MR; Woodford EC; Briker SM; Triebwasser JE; Gerber JS; Morris JS; Weirick ME; McAllister CM; Hensley SE; Puopolo KM
JAMA Netw Open; 2022 Nov; 5(11):e2240993. PubMed ID: 36350652
[TBL] [Abstract][Full Text] [Related]
58. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.
Badano MN; Sabbione F; Keitelman I; Pereson M; Aloisi N; Colado A; Ramos MV; Ortiz Wilczyñski JM; Pozner RG; Castillo L; Wigdorovitz G; E de Bracco MM; Fink S; Chuit R; Baré P
Mol Immunol; 2022 Mar; 143():94-99. PubMed ID: 35091231
[TBL] [Abstract][Full Text] [Related]
59. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
[TBL] [Abstract][Full Text] [Related]
60. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]